These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881 [TBL] [Abstract][Full Text] [Related]
6. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475 [TBL] [Abstract][Full Text] [Related]
7. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial. Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091 [TBL] [Abstract][Full Text] [Related]
8. Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial. Qi X; Li HZ; Gao XS; Qin SB; Zhang M; Li XM; Li XY; Ma MW; Bai Y; Li XY; Wang D Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):282-290. PubMed ID: 31669564 [TBL] [Abstract][Full Text] [Related]
9. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy. Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K Tumori; 2014; 100(3):265-71. PubMed ID: 25076236 [TBL] [Abstract][Full Text] [Related]
10. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722 [TBL] [Abstract][Full Text] [Related]
11. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014 [TBL] [Abstract][Full Text] [Related]
12. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855 [TBL] [Abstract][Full Text] [Related]
13. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients. D'Angelillo RM; Sciuto R; Ramella S; Papalia R; Jereczek-Fossa BA; Trodella LE; Fiore M; Gallucci M; Maini CL; Trodella L Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):296-302. PubMed ID: 25084612 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy. Narayan V; Vapiwala N; Mick R; Subramanian P; Christodouleas JP; Bekelman JE; Deville C; Rajendran R; Haas NB Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):355-361. PubMed ID: 27986349 [TBL] [Abstract][Full Text] [Related]
16. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736 [TBL] [Abstract][Full Text] [Related]
17. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580 [TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Pearse M; Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw A; Cheung P Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):792-8. PubMed ID: 18707818 [TBL] [Abstract][Full Text] [Related]
19. Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Ghadjar P; Hayoz S; Bernhard J; Zwahlen DR; Stein J; Hölscher T; Gut P; Polat B; Hildebrandt G; Müller AC; Putora PM; Papachristofilou A; Schär C; Dal Pra A; Biaggi Rudolf C; Wust P; Aebersold DM; Thalmann GN; Radiother Oncol; 2018 Feb; 126(2):257-262. PubMed ID: 29103826 [TBL] [Abstract][Full Text] [Related]
20. Salvage conformal radiotherapy for biochemical recurrent prostate cancer after radical prostatectomy. Monti CR; Nakamura RA; Ferrigno R; Rossi A; Kawakami NS; Trevisan FA Int Braz J Urol; 2006; 32(4):416-26; discussion 427. PubMed ID: 16953908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]